What is MyBiosource?
MyBiosource is a prominent supplier of research reagents and life science products, catering to a global base of researchers. The company's extensive catalog features over 2 million products, including ELISA kits, antibodies, and recombinant proteins, with a specialization in custom ELISA kit production. MyBiosource is particularly noted for its support of critical research areas, such as COVID-19, emphasizing rapid delivery and cost-effectiveness. This broad offering positions MyBiosource as a comprehensive resource for laboratories worldwide.
How much funding has MyBiosource raised?
MyBiosource has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in MyBiosource
PPP
Public-Private Partnership
What's next for MyBiosource?
With a substantial late-stage funding context, MyBiosource is poised for significant scaling and strategic advancement. The recent capital injection is likely to fuel further expansion of its product portfolio, enhancement of its research and development capabilities, and broader market penetration. The company's focus on serving critical health issues suggests that future investments may be directed towards accelerating the development and availability of essential research tools, solidifying its role as a key player in the global life science supply chain.
See full MyBiosource company page
